Related Experiment Video
Updated: Feb 1, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A
Allison C Nugent1, Kathleen E Wills1, Jessica R Gilbert1
1Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.
Abstract:
Preclinical and clinical evidence has demonstrated that ketamine has rapid antidepressant effects. Studies using pre-treatment with an AMPA inhibitor suggest that enhancing AMPA throughput is crucial to ketamine's effects, including increases in both basal and evoked gamma power. This study sought to replicate previous findings of increased gamma response to a somatosensory stimulus at 230 min and Day 1 in ketamine responders versus non-responders in 31 depressed subjects and 25 healthy controls. A significant difference in peak gamma power was seen in the depressed ketamine responders versus non-responders. These results implicate AMPA throughput in ketamine's mechanism of antidepressant action.
Related Concept Videos
Long-term Depression
Treatment Resistant Cancers
Synaptic Signaling
Chromosome Replication
Antidepressant Drugs: Overview
DNA Replication
Replication in Prokaryotes
DNA replication...

